Sébastien Campagne

Sébastien Campagne

Auto-generated profile, based on publicly available information

Sébastien Campagne

Univ. Bordeaux, CNRS, INSERM, ARNA, UMR 5320, U1212, Bordeaux, France

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 December 2020 in Nature Communications
Verified
Journal Article
Open access
PDF file
DJDaniel Jutzi
Daniel Jutzi
SCSébastien Campagne
Sébastien Campagne
RSRalf Schmidt
Ralf Schmidt
SRStefan Reber
Stefan Reber
JMJonas Mechtersheimer
Jonas Mechtersheimer
MRMarc-David Ruepp
Marc-David Ruepp
Mutations in the RNA-binding protein Fused in Sarcoma (FUS) cause early-onset amyotrophic lateral sclerosis (ALS). However, a detailed understanding of central RNA targets of FUS and their implications for disease remain elusive. Here, we use a unique blend of crosslinking and immunoprecipitation (CLIP) and NMR spectroscopy to identify and characterise physiological and pathological RNA targets of FUS. We find that U1 snRNA is the primary RNA target of FUS via its interaction with stem-loop 3 and provide atomic details of this RNA-mediated mode of interaction with the U1 snRNP. Furthermore, we show that ALS-associated FUS aberrantly contacts U1 snRNA at the Sm site with its zinc finger and traps snRNP biogenesis intermediates in human and murine motor neurons. Altogether, we present molecular insights into a FUS toxic gain-of-function involving direct and aberrant RNA-binding and strengthen the link between two motor neuron diseases, ALS and spinal muscular atrophy (SMA).

4 September 2023 in Nature Communications
Verified
Journal Article
Open access
PDF file
SCSébastien Campagne
Sébastien Campagne
DJDaniel Jutzi
Daniel Jutzi
FMFlorian Malard
Florian Malard
MMMaja Matoga
Maja Matoga
KRKsenija Romane
Ksenija Romane
FAFrederic Allain
Frederic Allain
Pharmacologic depletion of RNA-binding motif 39 (RBM39) using aryl sulfonamides represents a promising anti-cancer therapy but requires high levels of the adaptor protein DCAF15. Consequently, novel approaches to deplete RBM39 in an DCAF15-independent manner are required. Here, we uncover that RBM39 autoregulates via the inclusion of a poison exon into its own pre-mRNA and identify the cis-acting elements that govern this regulation. We also determine the NMR solution structures of RBM39’s tandem RNA recognition motifs (RRM1 and RRM2) bound to their respective RNA targets, revealing how RRM1 recognises RNA stem loops whereas RRM2 binds specifically to single-stranded N(G/U)NUUUG. Our results support a model where RRM2 selects the 3’-splice site of a poison exon and the RRM3 and RS domain stabilise the U2 snRNP at the branchpoint. Our work provides molecular insights into RBM39-dependent 3’-splice site selection and constitutes a solid basis to design alternative anti-cancer therapies.

15 November 2021 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
AJAndrew M Jobbins
Andrew M Jobbins
SCSébastien Campagne
Sébastien Campagne
RWRobert Weinmeister
Robert Weinmeister
CLChristian M Lucas
Christian M Lucas
AGAlison R Gosliga
Alison R Gosliga
IEIan C Eperon
Ian C Eperon
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

30 March 2024 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
FMFlorian Malard
Florian Malard
AWAntje C Wolter
Antje C Wolter
JMJulien Marquevielle
Julien Marquevielle
EMEstelle Morvan
Estelle Morvan
AEAgathe Ecoutin
Agathe Ecoutin
SCSebastien Campagne
Sebastien Campagne
Pharmacological modulation of RNA splicing by small molecules is an emerging facet of drug discovery. In this context, the SMN2 splicing modifier SMN-C5 was used as a prototype to understand the mode of action of small molecule splicing modifiers and propose the concept of 5′-splice site bulge repair. In this study, we combined in vitro binding assays and structure determination by NMR spectroscopy to identify the binding modes of four other small molecule splicing modifiers that switch the splicing of either the SMN2 or the HTT gene. Here, we determined the solution structures of risdiplam, branaplam, SMN-CX and SMN-CY bound to the intermolecular RNA helix epitope containing an unpaired adenine within the G-2A-1G+1U+2 motif of the 5′-splice site. Despite notable differences in their scaffolds, risdiplam, SMN-CX, SMN-CY and branaplam contact the RNA epitope similarly to SMN-C5, suggesting that the 5′-splice site bulge repair mechanism can be generalised. These findings not only deepen our understanding of the chemical diversity of splicing modifiers that target A-1 bulged 5′-splice sites, but also identify common pharmacophores required for modulating 5′-splice site selection with small molecules.

22 July 2022 in RNA Biology
Verified
Journal Article
Open access
FMFlorian Malard
Florian Malard
CMCameron Mackereth
Cameron Mackereth
SCSébastien Campagne
Sébastien Campagne
In Eukarya, immature mRNA transcripts (pre-mRNA) often contain coding sequences, or exons, interleaved by non-coding sequences, or introns. Introns are removed upon splicing, and further regulation of the retained exons leads to alternatively spliced mRNA. The splicing reaction requires the stepwise assembly of the spliceosome, a macromolecular machine composed of small nuclear ribonucleoproteins (snRNPs). This review focuses on the early stage of spliceosome assembly, when U1 snRNP defines each intron 5’-splice site (5ʹss) in the pre-mRNA. We first introduce the splicing reaction and the impact of alternative splicing on gene expression regulation. Thereafter, we extensively discuss splicing descriptors that influence the 5ʹss selection by U1 snRNP, such as sequence determinants, and interactions mediated by U1-specific proteins or U1 small nuclear RNA (U1 snRNA). We also include examples of diseases that affect the 5ʹss selection by U1 snRNP, and discuss recent therapeutic advances that manipulate U1 snRNP 5ʹss selectivity with antisense oligonucleotides and small-molecule splicing switches.

10 June 2022 in Nucleic Acids Research
Verified
Journal Article
Open access
PDF file
MDMichal Domanski
Michal Domanski
EDEmil Dedic
Emil Dedic
MPMaria Escura Pérez
Maria Escura Pérez
ACAntoine Cléry
Antoine Cléry
SCSébastien Campagne
Sébastien Campagne
OMOliver Mühlemann
Oliver Mühlemann
Heterogenous nuclear ribonucleoproteins (hnRNPs) are abundant proteins implicated in various steps of RNA processing that assemble on nuclear RNA into larger complexes termed 40S hnRNP particles. Despite their initial discovery 55 years ago, our understanding of these intriguing macromolecular assemblies remains limited. Here, we report the biochemical purification of native 40S hnRNP particles and the determination of their complete protein composition by label-free quantitative mass spectrometry, identifying A-group and C-group hnRNPs as the major protein constituents. Isolated 40S hnRNP particles dissociate upon RNA digestion and can be reconstituted in vitro on defined RNAs in the presence of the individual protein components, demonstrating a scaffolding role for RNA in nucleating particle formation. Finally, we revealed their nanometer scale, condensate-like nature, promoted by intrinsically disordered regions of A-group hnRNPs. Collectively, we identify nuclear 40S hnRNP particles as novel dynamic biomolecular condensates.